Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moti Ramgopal

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Lancet (London, England)|July 9, 2013
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyPedro Cahn, Anton L Pozniak, Horacio Mingrone, et al.
Lancet (London, England)|February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialChloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1Sharon A Riddler, Michael Para, Constance A Benson, et al.
The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
The New England Journal of Medicine|November 27, 2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Lancet (London, England)|July 9, 2013
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyPedro Cahn, Anton L Pozniak, Horacio Mingrone, et al.
Lancet (London, England)|February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialChloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1Sharon A Riddler, Michael Para, Constance A Benson, et al.
The Lancet. HIV|July 15, 2024
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trialDavid A Wohl, Christoph D Spinner, Jason Flamm, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
The New England Journal of Medicine|November 27, 2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 6